康希诺生物 CanSinoBIO

2021 Year

COVID-19 vaccine Convidecia, MCV2 and MCV4 received approval
2020 Year

Developed COVID-19 vaccine Convidecia; Successfully listed on STAR market of the Shanghai Stock Exchange
2019 Year

NDA for MCV2 was accepted by NMPA;
Listed on the Main Boary of HKEx;
NDA for MCV4 was granted with Priority Review designation
2018 Year

Completed commissioning of commercial manufacturing facility；
CTA approved for DTcP and PBPV；
Completed phase Ⅲ clinical trials for MCV2 and MCV4；
Filed CTA for Pcv13i；
2017 Year

Obtained NDA approval of Ad5-EBOV in China
2016 Year

Completed Ad5-EBOV Phase II clinical trial in Sierra Leone;
Submitted CTA of PBPV
2015 Year

Pilot facility passed EMA's QP inspection;
Obtained MCV2 & MCV4 CTA approvals
2014 Year

Filed CTA for DTcP candidates;
Obtained CTA approval of Ad5-EBOV and initiated clinical trial
2013 Year

Filed CTA for MCV2 & MCV4
2012 Year

Completed commissioning of pilot facility designed to meet the GMP
2009 Year

Incorporated and registered in Tianjin, China